Novartis to Acquire Myricx Bio for $1.1 Billion to Expand Oncology Portfolio

Key Facts

In a strategic move aimed at strengthening its position in advanced oncology, Swiss pharmaceutical giant Novartis has agreed to acquire UK-based Myricx Bio. According to updated reports, the transaction is valued at $1.1 billion and specifically targets the expansion of Novartis's cancer drug portfolio through Myricx's proprietary biotechnology assets. The deal is projected to close officially during the second half of 2026.

This acquisition aligns with a broader industry trend where major drugmakers are aggressively acquiring innovative platforms to offset looming patent expirations. This mirrors AstraZeneca's recent $2.4 billion acquisition of Fusion Pharmaceuticals per Reuters reports, emphasizing a sector-wide pivot toward targeted therapies. Per market data, the revised $1.1 billion valuation suggests a more calibrated assessment of biotech assets amid shifting market conditions.

Regarding market performance, NVS stock was priced at $159.9 (at close July 2, 2026), moving within a session range of $157 to $160.57. Investors will focus on upcoming regulatory filings for the merger, alongside Swiss economic catalysts such as the KOF Leading Indicators, which recently printed at 101.2, serving as a key sentiment driver for Swiss-listed blue chips.